FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2249879423> ?p ?o ?g. }

• W2249879423 endingPage "7516" @default.
• W2249879423 startingPage "7516" @default.
• W2249879423 abstract "7516 Background: C225 is a chimerized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). NSCLC commonly expresses the EGFR, which is associated with aggressive tumor behavior and poor clinical outcome. Preclinical model systems demonstrate radiosensitization following molecular inhibition of EGFR signaling. Methods: We report a phase II trial testing the combination of C225 with CRT in unresectable stage III NSCLC with a planned sample size of 84 PTS. Eligibility criteria included Zubrod performance status (PS) ≤ 1, weight loss ≤ 5% over past 3 months, FEV1 ≥ 1.2 L, adequate hematologic, hepatic, and renal function. PTS received an initial dose of C225 (400 mg/m2) on day 1 of wk 1, then wkly doses of C225 (250 mg/m2) until completion of therapy (wks 2 - 17). During wk 2, PTS started CRT (63 Gy/35 fractions) with wkly carboplatin (C) AUC 2 and paclitaxel (P) 45 mg/m2 x 6 doses followed by C (AUC 6) and P (200 mg/m2) x 2 cycles (wks 12–17). Interim monitoring for severe (grade ≥ 3) or excessive non-hematologic toxicities occurred after PTS had been treated and followed for at least 90 days after RT. Primary endpoints include safety and compliance of concurrent C225 and CRT. Results: 93 PTS were enrolled with 87 evaluable PTS. PTS characteristics: 57% male, median age 64 years (range 42–85), 47% PS 0, 46% stage IIIA. Median follow-up is 21.6 months (M). Response rate is 62% (n=54), MS is 22.7 M, and 24 M overall survival (OS) is 49.3%(# at risk=40). Adverse events related to treatment include 20%(n=17) of PTS with grade (G) 4 hematologic toxicities, 8% (n=7 PTS) G 3 esophagitis, and 7% (n=6 PTS) G 3–4 pneumonitis. There were 5 G 5 events. Conclusions: The combination of C225 with CRT is feasible and active with MS and OS better than any previously reported by the RTOG. These results warrant confirmation in a randomized trial. Complete compliance, toxicity, and updated survival data will be reported. Supported by RTOG U10 CA21661, CCOP U10 CA37422, and Stat U10 CA32115 grants from the NCI. This abstract's contents are the sole responsibility of the authors and do not necessarily represent the official views of the NCI. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Bristol-Myers Squibb, ImClone Systems Incorporated Bristol-Myers Squibb, ImClone Systems Incorporated Bayer, Bristol-Myers Squibb, Eli Lilly" @default.
• W2249879423 created "2016-06-24" @default.
• W2249879423 creator A5009466654 @default.
• W2249879423 creator A5026088869 @default.
• W2249879423 creator A5031061740 @default.
• W2249879423 creator A5038656833 @default.
• W2249879423 creator A5039663311 @default.
• W2249879423 creator A5059919595 @default.
• W2249879423 creator A5066993165 @default.
• W2249879423 creator A5078366847 @default.
• W2249879423 creator A5086655595 @default.
• W2249879423 date "2008-05-20" @default.
• W2249879423 modified "2023-09-26" @default.
• W2249879423 title "A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): A report of the 2 year and median survival (MS) for the RTOG 0324 trial" @default.
• W2249879423 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.7516" @default.
• W2249879423 hasPublicationYear "2008" @default.
• W2249879423 type Work @default.
• W2249879423 sameAs 2249879423 @default.
• W2249879423 citedByCount "19" @default.
• W2249879423 countsByYear W22498794232013 @default.
• W2249879423 countsByYear W22498794232014 @default.
• W2249879423 crossrefType "journal-article" @default.
• W2249879423 hasAuthorship W2249879423A5009466654 @default.
• W2249879423 hasAuthorship W2249879423A5026088869 @default.
• W2249879423 hasAuthorship W2249879423A5031061740 @default.
• W2249879423 hasAuthorship W2249879423A5038656833 @default.
• W2249879423 hasAuthorship W2249879423A5039663311 @default.
• W2249879423 hasAuthorship W2249879423A5059919595 @default.
• W2249879423 hasAuthorship W2249879423A5066993165 @default.
• W2249879423 hasAuthorship W2249879423A5078366847 @default.
• W2249879423 hasAuthorship W2249879423A5086655595 @default.
• W2249879423 hasConcept C121608353 @default.
• W2249879423 hasConcept C126322002 @default.
• W2249879423 hasConcept C126894567 @default.
• W2249879423 hasConcept C143998085 @default.
• W2249879423 hasConcept C203092338 @default.
• W2249879423 hasConcept C2776256026 @default.
• W2249879423 hasConcept C2776694085 @default.
• W2249879423 hasConcept C2778239845 @default.
• W2249879423 hasConcept C2779998722 @default.
• W2249879423 hasConcept C2781451048 @default.
• W2249879423 hasConcept C31760486 @default.
• W2249879423 hasConcept C526805850 @default.
• W2249879423 hasConcept C535046627 @default.
• W2249879423 hasConcept C71924100 @default.
• W2249879423 hasConcept C90924648 @default.
• W2249879423 hasConceptScore W2249879423C121608353 @default.
• W2249879423 hasConceptScore W2249879423C126322002 @default.
• W2249879423 hasConceptScore W2249879423C126894567 @default.
• W2249879423 hasConceptScore W2249879423C143998085 @default.
• W2249879423 hasConceptScore W2249879423C203092338 @default.
• W2249879423 hasConceptScore W2249879423C2776256026 @default.
• W2249879423 hasConceptScore W2249879423C2776694085 @default.
• W2249879423 hasConceptScore W2249879423C2778239845 @default.
• W2249879423 hasConceptScore W2249879423C2779998722 @default.
• W2249879423 hasConceptScore W2249879423C2781451048 @default.
• W2249879423 hasConceptScore W2249879423C31760486 @default.
• W2249879423 hasConceptScore W2249879423C526805850 @default.
• W2249879423 hasConceptScore W2249879423C535046627 @default.
• W2249879423 hasConceptScore W2249879423C71924100 @default.
• W2249879423 hasConceptScore W2249879423C90924648 @default.
• W2249879423 hasIssue "15_suppl" @default.
• W2249879423 hasLocation W22498794231 @default.
• W2249879423 hasOpenAccess W2249879423 @default.
• W2249879423 hasPrimaryLocation W22498794231 @default.
• W2249879423 hasRelatedWork W1607236184 @default.
• W2249879423 hasRelatedWork W2060263774 @default.
• W2249879423 hasRelatedWork W2081714604 @default.
• W2249879423 hasRelatedWork W2139697170 @default.
• W2249879423 hasRelatedWork W2313154800 @default.
• W2249879423 hasRelatedWork W2423163941 @default.
• W2249879423 hasRelatedWork W2586937224 @default.
• W2249879423 hasRelatedWork W2597378792 @default.
• W2249879423 hasRelatedWork W2790212231 @default.
• W2249879423 hasRelatedWork W2898107451 @default.
• W2249879423 hasVolume "26" @default.
• W2249879423 isParatext "false" @default.
• W2249879423 isRetracted "false" @default.
• W2249879423 magId "2249879423" @default.
• W2249879423 workType "article" @default.